ELVN
Enliven Therapeutics, Inc.
Industry
Biotechnology
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Loading...
Open
23.60
Mkt cap
1.2B
Volume
210K
High
24.42
P/E Ratio
-12.90
52-wk high
30.03
Low
22.92
Div yield
N/A
52-wk low
10.90

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.